Blood Tests for Inflammation Can Be Discordant
|
By LabMedica International staff writers Posted on 30 Oct 2012 |
The erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels are widely used tests of inflammation that sometimes show opposite results.
However, CRP and ESR may not correlate substantially in some conditions, and the extent to which CRP and ESR results agree with each other in an unselected patient population is not clear in clinical practice, as the results of the two tests are sometimes different.
Scientists at the Texas Health Presbyterian Hospital (Dallas, TX, USA) performed 2,150 paired CRP/ESR measurements in 1,753 patients, between January and December of 2011. There were 1,731 patients who were not pregnant and were all adults aged 18 years or more. Initial CRP and ESR results for each patient were divided into quartiles.
The CRP assay performed is based on a reaction between CRP in a serum or plasma sample and polyclonal anti-CRP antibodies that have been adsorbed to latex particles the Multigent CRP Vario Reagent, (Sentinel; Milan, Italy). Agglutination is detected as an absorbance change at 572 nm on the Architect c8000 (Abbott Laboratories; Abbott Park, IL, USA). The ESR assay samples are read with an ESR-Auto Plus instrument in QuickMode (Streck; Omaha, NE, USA) and converted to Westergren units. The results can range from zero to greater than 120 mm/hour.
The ages of the 105 patients in the high CRP/low ESR–discordant group and the 107 in the high ESR/low CRP–discordant group were similar. The high CRP/low ESR–discordant group had more patients with infections than the high ESR/low CRP–discordant group particularly infections in the urinary tract, gastrointestinal tract, lungs and bloodstream. However, they had fewer bone and joint infections than the high ESR/low CRP–discordant group.
Connective tissue diseases, such as systemic lupus erythematosus, were less common in the high CRP/low ESR–discordant group than in the high ESR/low CRP–discordant group. Ischemic strokes or transient ischemic attacks almost invariably occurred in the high ESR/low CRP–discordant group, whereas myocardial infarction or venous thromboembolism was limited to the high CRP/low ESR–discordant group. The authors concluded that their findings will provide information to physicians who order these two tests together and receive discordant results, which occurs in approximately one in eight patients. The study was published on August 23, 2012, in the journal Translational Research.
Related Links:
Texas Health Presbyterian Hospital
Sentinel
Abbott Laboratories
However, CRP and ESR may not correlate substantially in some conditions, and the extent to which CRP and ESR results agree with each other in an unselected patient population is not clear in clinical practice, as the results of the two tests are sometimes different.
Scientists at the Texas Health Presbyterian Hospital (Dallas, TX, USA) performed 2,150 paired CRP/ESR measurements in 1,753 patients, between January and December of 2011. There were 1,731 patients who were not pregnant and were all adults aged 18 years or more. Initial CRP and ESR results for each patient were divided into quartiles.
The CRP assay performed is based on a reaction between CRP in a serum or plasma sample and polyclonal anti-CRP antibodies that have been adsorbed to latex particles the Multigent CRP Vario Reagent, (Sentinel; Milan, Italy). Agglutination is detected as an absorbance change at 572 nm on the Architect c8000 (Abbott Laboratories; Abbott Park, IL, USA). The ESR assay samples are read with an ESR-Auto Plus instrument in QuickMode (Streck; Omaha, NE, USA) and converted to Westergren units. The results can range from zero to greater than 120 mm/hour.
The ages of the 105 patients in the high CRP/low ESR–discordant group and the 107 in the high ESR/low CRP–discordant group were similar. The high CRP/low ESR–discordant group had more patients with infections than the high ESR/low CRP–discordant group particularly infections in the urinary tract, gastrointestinal tract, lungs and bloodstream. However, they had fewer bone and joint infections than the high ESR/low CRP–discordant group.
Connective tissue diseases, such as systemic lupus erythematosus, were less common in the high CRP/low ESR–discordant group than in the high ESR/low CRP–discordant group. Ischemic strokes or transient ischemic attacks almost invariably occurred in the high ESR/low CRP–discordant group, whereas myocardial infarction or venous thromboembolism was limited to the high CRP/low ESR–discordant group. The authors concluded that their findings will provide information to physicians who order these two tests together and receive discordant results, which occurs in approximately one in eight patients. The study was published on August 23, 2012, in the journal Translational Research.
Related Links:
Texas Health Presbyterian Hospital
Sentinel
Abbott Laboratories
Latest Clinical Chem. News
- New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
- Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
- Study Compares Analytical Performance of Quantitative Hepatitis B Surface Antigen Assays
- Blood Test Could Predict and Identify Early Relapses in Myeloma Patients
- Compact Raman Imaging System Detects Subtle Tumor Signals
- Noninvasive Blood-Glucose Monitoring to Replace Finger Pricks for Diabetics
- POC Breath Diagnostic System to Detect Pneumonia-Causing Pathogens
- Online Tool Detects Drug Exposure Directly from Patient Samples
- Chemical Imaging Probe Could Track and Treat Prostate Cancer
- Mismatch Between Two Common Kidney Function Tests Indicates Serious Health Problems
- VOCs Show Promise for Early Multi-Cancer Detection
- Portable Raman Spectroscopy Offers Cost-Effective Kidney Disease Diagnosis at POC
- Gold Nanoparticles to Improve Accuracy of Ovarian Cancer Diagnosis
- Simultaneous Cell Isolation Technology Improves Cancer Diagnostic Accuracy
- Simple Non-Invasive Hair-Based Test Could Speed ALS Diagnosis
- Paper Strip Saliva Test Detects Elevated Uric Acid Levels Without Blood Draws
Channels
Molecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







